Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mulligan

Showing results (231-240 of 245) with videos related to

Pageof 25
Sort By:
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
British Journal of Haematology|August 31, 2006
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarrayLarissa Belov, Stephen P Mulligan, Nicole Barber, et al.
Nature Cell Biology|September 8, 2022
Comparative roadmaps of reprogramming and oncogenic transformation identify Bcl11b and Atoh8 as broad regulators of cellular plasticityA Huyghe, G Furlan, J Schroeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
The Medical Journal of Australia|May 14, 2020
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceRobert Weinkove, Zoe K McQuilten, Jonathan Adler, et al.
Mycoses|September 15, 2019
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational studyRosa Ruchlemer, Ronen Ben-Ami, Maskit Bar-Meir, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
ACS Central Science|August 29, 2022
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative InfectionsErica N Parker, Brett N Cain, Behnoush Hajian, et al.
Pageof 25

Showing results (231-240 of 245) with videos related to

Sort By:
Pageof 25
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Internal Medicine Journal|September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statementMary A Anderson, Rory Bennett, Xavier Badoux, et al.
British Journal of Haematology|August 31, 2006
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarrayLarissa Belov, Stephen P Mulligan, Nicole Barber, et al.
Nature Cell Biology|September 8, 2022
Comparative roadmaps of reprogramming and oncogenic transformation identify Bcl11b and Atoh8 as broad regulators of cellular plasticityA Huyghe, G Furlan, J Schroeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
The Medical Journal of Australia|May 14, 2020
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidanceRobert Weinkove, Zoe K McQuilten, Jonathan Adler, et al.
Mycoses|September 15, 2019
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational studyRosa Ruchlemer, Ronen Ben-Ami, Maskit Bar-Meir, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
ACS Central Science|August 29, 2022
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative InfectionsErica N Parker, Brett N Cain, Behnoush Hajian, et al.
Pageof 25